Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma 3Neoplasms 2Lung Neoplasms 2Head and Neck Neoplasms 2Vulvar Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Teratoma, Ovarian 1Struma Ovarii 1Salivary Gland Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Myelodysplastic Syndromes 1Metabolic Syndrome 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia 1Hemangioma, Cavernous, Central Nervous System 1Glioblastoma 1Genetic Predisposition to Disease 1Disease 1Diabetes Mellitus 1Cytopenia 1Cardiovascular Diseases 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Astrocytoma 1

Interventions

Temozolomide 74Radiotherapy 34Carboplatin 21Bevacizumab 18Magnetic Resonance Spectroscopy 17Irinotecan 16Carmustine 16Vincristine 14Surgical Procedures, Operative 13Filgrastim 13Procarbazine 10Erlotinib Hydrochloride 8Cyclophosphamide 8Peripheral Blood Stem Cell Transplantation 7O(6)-benzylguanine 7Lomustine 7Etoposide 7sargramostim 6Imatinib Mesylate 6Flucytosine 6Cisplatin 62-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 6temsirolimus 5Vorinostat 5Thiotepa 5Radiotherapy, Intensity-Modulated 5Radiation 5Immunohistochemistry 5Biopsy 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Oligodendroglioma × DNA × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡